Authors: Doriane Henry, Eric Baugé, Nathalie Hennuyer, Kevin Ory, Bruno Derudas, Emmanuelle Vallez, Audrey Deprince, Philippe Lefebvre, Joel T. Haas, Bart Staels, Fanny Lalloyer
Published: 2025-05-28
DOI: 10.1126/scitranslmed.adj8192
Source: Full article
Atherogenic dyslipidemia and chronic inflammation appear strongly associated with residual cardiovascular disease (CVD) risk. Peroxisome proliferator–activated receptor α (PPARα) agonists, which exert both triglyceride-lowering and anti-inflammatory properties, are potential therapeutic candidates to target residual CVD risk. However, CVD outcome studies with these drugs have yielded mixed results for currently unclear reasons. In this study, we compared the impact of hepatocyte anti-inflammatory (transrepression) versus lipid-lowering (transactivation) properties of PPARα agonism on atherosclerosis in